| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 144, 177-187, Copyright © 1994 by American Society for Investigative Pathology
REGULAR ARTICLES |
V Askanas, WK Engel, M Bilak, RB Alvarez and DJ Selkoe
Department of Neurology, University of Southern California School of Medicine, Los Angeles.
We immunostained muscle biopsies of 8 patients with sporadic inclusion body myositis (S-IBM), 7 patients with autosomal recessive hereditary inclusion body myopathy (H-IBM) (both diseases being characterized by similar muscle fiber vacuoles containing inclusions), and 11 normal and disease controls. We used the following well-characterized antibodies against tau protein: Tau-1, Alz-50, and anti-paired helical filament (PHF) antiserum. By light microscopy, in all S-IBM muscle biopsies virtually all vacuoles immunoreactive for ubiquitin and beta-amyloid protein also contained inclusions immunoreactive with Alz-50 and anti- PHF antiserum. With tau-1 antibody, strong immunoreactivity in the vacuoles was obtained only after dephosphorylation of muscle sections. By electronmicroscopy, all three antibodies immunodecorated exclusively cytoplasmic twisted tubulofilaments (TTFs). In H-IBM, virtually all ubiquitin and beta-amyloid-positive muscle fiber vacuoles contained inclusions immunoreactive with anti-PHF antiserum, but in only 40% of those fibers were the inclusions immunoreactive with Alz-50. In six H- IBM patients there were no tau-1 immunoreactive inclusions in any of their vacuolated muscle fibers; in one patient, 24% of the vacuolated fibers had tau-1 immunoreactivity. By demonstrating that hyperphosphorylated tau, which is characteristic of Alzheimer brain PHFs, is a component of S-IBM-muscle TTFs (which are also ultrastructurally similar to PHFs), our study: 1) provides the first demonstration of abnormally accumulated tau in nonneural tissue and 2) suggests that the cytopathogenesis in Alzheimer brain and S-IBM muscle may share some similar mechanisms. Whether the difference in tau immunoreactivity between S-IBM and most of the H-IBM patients reflects a difference in genetically determined transcriptional or posttranslational modifications of tau protein or other factors remains to be determined.
This article has been cited by other articles:
 |
|
 |
|
  W. K. Engel and V. Askanas Inclusion-body myositis: Clinical, diagnostic, and pathologic aspects Neurology, January 24, 2006; 66(1_suppl_1): S20 - S29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Greenberg, D. Sanoudou, J. N. Haslett, I. S. Kohane, L. M. Kunkel, A. H. Beggs, and A. A. Amato Molecular profiles of inflammatory myopathies Neurology, October 22, 2002; 59(8): 1170 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Sugarman, T. R. Yamasaki, S. Oddo, J. C. Echegoyen, M. P. Murphy, T. E. Golde, M. Jannatipour, M. A. Leissring, and F. M. LaFerla Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle PNAS, April 30, 2002; 99(9): 6334 - 6339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Randomized pilot trial of {beta}INF1a (Avonex) in patients with inclusion body myositis Neurology, November 13, 2001; 57(9): 1566 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Li and M. C. Dalakas The muscle mitogen-activated protein kinase is altered in sporadic inclusion body myositis Neurology, April 25, 2000; 54(8): 1665 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Broccolini, W. K. Engel, R. B. Alvarez, and V. Askanas Paired Helical Filaments of Inclusion-Body Myositis Muscle Contain RNA and Survival Motor Neuron Protein Am. J. Pathol., April 1, 2000; 156(4): 1151 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kuwahara, N. Araki, K. Makino, N. Masuko, S. Honda, K. Kaibuchi, K. Fukunaga, E. Miyamoto, M. Ogawa, and H. Saya A Novel NE-dlg/SAP102-associated Protein, p51-nedasin, Related to the Amidohydrolase Superfamily, Interferes with the Association between NE-dlg/SAP102 and N-Methyl-D-aspartate Receptor J. Biol. Chem., November 5, 1999; 274(45): 32204 - 32214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nakano, I. Akiguchi, S. Nakamura, H. Satoi, S. Kawashima, and J. Kimura Aberrant expression of cyclin-dependent kinase 5 in inclusion body myositis Neurology, November 1, 1999; 53(8): 1671 - 1671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Askanas and W. K. Engel Does Overexpression of ßAPP in Aging Muscle Have a Pathogenic Role and a Relevance to Alzheimer's Disease? : Clues from Inclusion Body Myositis, Cultured Human Muscle, and Transgenic Mice Am. J. Pathol., December 1, 1998; 153(6): 1673 - 1677. [Full Text] [PDF]
|
|
|
|
|
|
L.-W. Jin, M. G. Hearn, C. E. Ogburn, N. Dang, D. Nochlin, W. C. Ladiges, and G. M. Martin Transgenic Mice Over-Expressing the C-99 Fragment of ßPP with an {alpha}-Secretase Site Mutation Develop a Myopathy Similar to Human Inclusion Body Myositis Am. J. Pathol., December 1, 1998; 153(6): 1679 - 1686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Fukuchi, D. Pham, M. Hart, L. Li, and J. R. Lindsey Amyloid-ß Deposition in Skeletal Muscle of Transgenic Mice : Possible Model of Inclusion Body Myopathy Am. J. Pathol., December 1, 1998; 153(6): 1687 - 1693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Sugarman, T. R. Yamasaki, S. Oddo, J. C. Echegoyen, M. P. Murphy, T. E. Golde, M. Jannatipour, M. A. Leissring, and F. M. LaFerla Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle PNAS, April 30, 2002; 99(9): 6334 - 6339. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
